May 17, 2020

Pamlab Joins Nestlé's Growing Heath-related Acquisitions

Health
healthcare
Medical Foods
Nestlé Health Scie
Admin
2 min
Nestlé adds to its growing portfolio
News of Nestlé Health Sciences latest acquisition came Tuesday with its agreement to purchase Pamlab, a medical foods manufacturer. For an undis...

News of Nestlé Health Science’s latest acquisition came Tuesday with its agreement to purchase Pamlab, a medical foods manufacturer. For an undisclosed amount, the U.S.-based company – whose products treat patients with conditions like depression, diabetic peripheral neuropathy, dementia, and high-risk pregnancy – will be added to Nestlé’s portfolio, in line with its goals to expand into the health and nutrition industry.

“The acquisition of the Pamlab business is aligned with our strategic ambition to provide science-based nutritional solutions for people with chronic medical conditions,” Luis Cantarell, head of Nestlé Health Science, said in a statement.

As reported in Food Digital last summer, the world’s biggest food group is adapting to better meet the needs of a burgeoning customer base: a swiftly growing aging population. Since establishing Nestlé Health Science, a full own subsidiary of Nestlé in 2011, improving brain health has been at the forefront of the Swiss-based firm’s recent interests.

"Pamlab will particularly strengthen our brain health platform and provide us an additional foothold in metabolic health in the U.S.," said Cantarell. “By leveraging our nutrition heritage and US operations with Pamlab’s proven expertise in medical foods and strong sales force capabilities, together we can play a key role in helping to manage certain chronic diseases and improve the quality of patients’ lives.”

Nestlé: What Does “Good Food, Good Life” Mean to You?

Recent acquisitions by Nestlé include CM&D Pharma Ltd., maker of a chewing gum designed for patients with compromised kidney function, inflammatory bowel disease medication-maker Prometheus Laboratories, and another medical foods developer, Accera. Accera’s products include a “milk shake” to manage and improve symptoms of Alzheimer’s disease.

Tackling the treatment of diseases and conditions that often greatly reduce quality of life adds a whole new facet to the meaning of Nestlé’s long-standing motto: “Good Food, Good Life.”

“We are excited to join forces with Nestlé Health Science, and we share their commitment to personalized nutrition,” said Eric Wingerter, Pamlab President and Chief Executive Officer.

“With their support, we will accelerate the development and deployment of our innovative nutritional solutions for people with chronic metabolic and neurologic conditions. We are united by a common purpose, and a common culture, founded on our passion for patients to make a difference in people’s lives.”

Images sourced via Flickr: Nestlé

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

AI
NHS
skincancer
Cancer
2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article